Lenacapavir

Overview

Lenacapavir is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4594438).

Patent & exclusivity (US)

Per the FDA Orange Book (4 approved US products), the latest listed US patent on Lenacapavir expires 28 Aug 2041 and exclusivity 18 Jun 2028. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

N-[(1S)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide

Canonical SMILES

CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)(F)F)NS(=O)(=O)C)[C@H](CC4=CC(=CC(=C4)F)F)NC(=O)CN5C6=C([C@H]7C[C@H]7C6(F)F)C(=N5)C(F)(F)F)S(=O)(=O)C

InChIKey

BRYXUCLEHAUSDY-WEWMWRJBSA-N